The human monoclonal antibody golimumab (Simponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1 year, newly ...
LOS ANGELES, Dec 21 (Reuters) - Johnson & Johnson and Schering-Plough Corp said on Friday their distribution agreement for rheumatoid arthritis treatment Remicade and golimumab, J&J's next-generation ...
Combination treatment with guselkumab (Tremfya) plus golimumab (Simponi) may hold an advantage over use of either agent alone for patients with moderate-to-severe ulcerative colitis, results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results